Novo Nordisk A/S (NYSE:NVO) has received approval in China for Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH), making it the first GLP-1 receptor agonist approved in the country for the liver disease. The approval expands Wegovy’s potential beyond weight management and cardiovascular benefits into another major condition linked to obesity. Reuters noted that Novo sees the decision as further evidence of Wegovy’s broader role in treating complications associated with obesity.
The approval is particularly important because China represents a large potential market for GLP-1 treatments. The market is also becoming more competitive, with Chinese drugmakers developing their own GLP-1 medicines and putting pressure on prices.
The Wall Street Journal recently reported that Novo Nordisk A/S’s GLP-1 sales in China declined 8% in 2025 amid intense competition. Pricing pressure and the expiration of semaglutide’s Chinese patent could make the market even more challenging.
First-Mover Advantage Gives Novo an Edge in China’s MASH Market
The biggest positive is that Novo is adding another indication for its most important growth product. MASH is closely linked to obesity and metabolic disease, so Wegovy could reach patients who need treatment for both weight management and liver disease. Being the first GLP-1 approved for MASH in China also gives Novo an early advantage while competitors work on developing or getting approval for similar treatments.
The approval also supports the idea that Wegovy can become a broader metabolic-health treatment rather than simply a weight-loss drug. Novo already has evidence of Wegovy’s cardiovascular benefits, and Reuters has reported that the drug has also received approval for MASH in the U.S.Adding more approved uses could help Novo get more value from its semaglutide franchise and extend its growth potential.
China could also provide another source of growth as Novo Nordisk A/S looks to diversify beyond its core obesity and diabetes business. The company has been pursuing an oral version of Wegovy in China as well, which could give it another way to reach patients who prefer pills over injections.
Domestic Rivals Could Challenge Wegovy’s China Opportunity
The approval does not necessarily mean a major increase in revenue. China’s GLP-1 market is becoming increasingly competitive, with nearly 250 Chinese GLP-1 treatments reportedly in development. Local drugmakers also have lower operating costs and can move quickly through clinical development. That could put more pressure on multinational companies such as Novo Nordisk A/S and make it harder to maintain higher prices.
Pricing is a particularly important risk. The Wall Street Journal reported that obesity drugs in China have limited insurance coverage, meaning many patients have to pay out of pocket. Novo has already faced pressure on its GLP-1 sales and has lowered prices for some products.
Even with the MASH approval, Wegovy could therefore generate less revenue per patient in China than it does in markets where drug prices are higher. There is also a broader concern about Novo’s dependence on its obesity business. Recent setbacks in the company’s efforts to expand into other areas, including the termination of two additional cardiovascular trials for ziltivekimab, have made Wegovy and related products even more important to Novo’s future growth.
Conclusion
The China MASH approval is clearly bullish for Novo Nordisk A/S strategically. It expands Wegovy into another major obesity-related disease and gives the company first-mover status among GLP-1 drugs for MASH in China. It also strengthens the case for Wegovy to become a broader metabolic-health treatment rather than remaining mainly a weight-loss product.
The financial impact may take longer to show. Strong competition from Chinese drugmakers, lower prices, limited reimbursement and a growing domestic drug pipeline could limit how much revenue Novo generates from the opportunity. Overall, the approval strengthens Novo’s long-term Wegovy story, but the size of the financial benefit will depend on pricing, patient adoption and Novo’s ability to defend its position against increasingly capable Chinese competitors.
READ NEXT: IBM Takes its AI Strategy Beyond Earth with NASA Lunar Model and The Cooper Companies (COO) Faces Near-Term Pressure from Slowing Contact Lens Demand
This article is originally published at Insider Monkey.
